

Completed EHDN Endorsed Trials and Studies (updated June 2024)										
Registration ID (CT.gov)	Sponsor	Trial name	Phase	Intervention	Mode of Action	Delivery	Treatment Goal	Target Enrolment	Location(s)	Status
NCT02535884	Heinrich-Heine University, Düsseldorf	HD-DBS	2	Deep brain stimulation	High-frequency stimulation of the Globus Pallidus	Surgical, implant	Symptomatic	50	Austria, Germany, Switzerland	Completed
NCT04406636	Triplet Therapeutics/CHDI Foundation, Inc	SHIELD-HD	N/A	N/A	N/A	N/A	Natural History	70	US, Germany, UK, Canada, France	Completed
ISRCTN12103732	Cardiff University	DOMINO-HD	N/A	N/A	N/A	N/A	Feasibility and symptomatic	300	Poland, Spain, Switzerland, UK	Completed
NCT05111249	Novartis	VIBRANT-HD	2b, OLE*	Branaplam	mRNA splicing modifier	Oral	Disease modification	75	Belgium, Canada, Germany, Hungary, Italy, Spain, UK, USA	Terminated; completed.
NCT03761849	Roche	GENERATION-HD1	3	RO7234292 (RG6042) (tominersen)	htt lowering ASO	Intrathecal	Disease modification	899	North America, Europe, Oceania, Japan, Latin America	Completed
NCT03842969	Roche	GEN-EXTEND	OLE*	RO7234292 (RG6042) (tominersen)	htt lowering ASO	Intrathecal	Disease modification	236	North America, Europe	Completed
NCT03225833	Wave Life Sciences	PRECISION-HD1	1b/2a	WVE-120101	Allele-selective htt lowering ASO	Intrathecal	Disease modification	61	Australia, Canada, Denmark, France, Germany, Poland, UK	Completed
NCT03225846	Wave Life Sciences	PRECISION-HD2	1b/2a	WVE-120102	Allele-selective htt lowering ASO	Intrathecal	Disease modification	88	Australia, Canada, Denmark, France, Germany, Poland, UK	Completed
NCT04617847	Wave Life Sciences	PRECISION-HD1 OLE*	1b/2a, OLE*	WVE-120101	Allele-selective htt lowering ASO	Intrathecal	Disease modification	27	Australia, Canada, Denmark, France, Germany, Poland, UK	Completed
NCT04617860	Wave Life Sciences	PRECISION-HD2 OLE*	1b/2a, OLE*	WVE-120102	Allele-selective htt lowering ASO	Intrathecal	Disease modification	36	Australia, Canada, Denmark, France, Germany, Poland, UK	Completed
NCT03344601	Cardiff University	PACE-HD	N/A	Physical Therapy	N/A	N/A	Feasibility and acceptance	116	UK, US, Spain, Germany	Completed
NCT02197130	Pfizer	Amaryllis	2	PF-02545920	Phosphodiesterase 10A Inhibitor	Oral	Disease modification	272	North America, Europe	Completed
NCT00920946	Medivation, Inc	Horizon	3	Dimebon/latrepirdine	Developed as antihistamine, /cholinesterase inhibitor	Oral	Disease modification	403	US, UK, Denmark, Canada, Australia, Germany, Sweden	Completed
NCT01914965	Charite University	ACTION-HD	2	Bupropion	Dual inhibition of norepinephrine and dopamine reuptake	Oral	Symptomatic	40	Germany	Completed
NCT02519036	Ionis Pharmaceuticals, Inc.	IONIS-HTTRx	1/2	ISIS 443139 (tominersen)	htt lowering ASO	Intrathecal	Disease modification	46	Canada, Germany, UK	Completed
NCT02215616	Teva	LEGATO-HD	2	Laquinimod	Immuno-modulatory and neuro-protective effects	Oral	Disease modification	352	North America, Europe	Completed
NCT02006472	Teva	PRIDE-HD	2	Pridopidine	Dopaminergic stabiliser	Oral	Symptomatic	408	North America, Europe, Australia	Completed
NCT02494778	Teva	OPEN PRIDE-HD	OLE*	Pridopidine	Dopaminergic stabiliser	Oral	Symptomatic	248	North America, Europe, Australia	Terminated
NCT01521585	Siena BioTech	Selisistat	2	Selisistat, SEN0014196	Sirt1 inhibitor	Oral	Disease modification	144	Germany	Completed
NCT00146211	Amarin Neuroscience Ltd	TREND-HD	3	Ethyl-EPA	Unknown	Oral	Symptomatic	300	North America, Europe	Completed
ISRCTN94284668	Cardiff University	TRAIN-HD	2	Physical therapy	Unknown	Physical activity	Symptomatic	30	UK	Completed
ISRCTN65378754	Cardiff University	ENGAGE-HD	N/A	Physical therapy	Unknown	Physical activity	Feasibility	46	UK	Completed
ISRCTN11392629	Cardiff University	ExeRT-HD	2	Physical therapy	Unknown	Physical activity	Feasibility	32	UK	Completed
NCT01590589	EHDN	REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)	N/A	N/A	N/A	N/A	Natural History	14860	Europe	Completed
NCT02061722	CHDI Foundation, Inc.	PEARL-HD	Early phase 1	[18F]MNI-659	PDE10A enzyme availability	Intravenous	Biomarker	90	Denmark, Netherlands, Norway, Sweden	Completed
NCT02956148	CHDI Foundation, Inc.	LONG PDE10A	Early phase 1	[18F]MNI-659	PDE10A enzyme availability	Intravenous	Biomarker	45	Denmark, Netherlands, Norway, Sweden	Completed
Note. ASO = antisense oligonucleotide; htt= huntingtin; mRNA = messenger ribonucleic acid; OLE = open-label extension;										